Shanghai – June 26, 2018 – Cooley advised CStone Pharmaceuticals on its exclusive collaboration and license agreement with Blueprint Medicines to develop and commercialize its cancer therapy, avapritnib, in mainland China, Hong Kong, Macau and Taiwan. Partner Christina Zhang led the Cooley team advising CStone.
Under the terms of the agreement, CStone will make an upfront payment of $40 million in cash to Blueprint. Blueprint is also eligible to receive approximately $346 million in potential milestone payments in addition to tiered percentage royalties.
"Based on the compelling clinical data reported to date, we believe Blueprint Medicines' targeted therapies – avapritinib, BLU-554 and BLU-667 – hold promise for dramatically altering the treatment landscape for patients in China with gastrointestinal stromal tumors, hepatocellular carcinoma, non-small cell lung cancer and other cancers,” said Frank Jiang, CStone’s chief executive officer, in a news release.
CStone is a Shanghai and Suzhou-based innovative biopharmaceutical company devoted to the development of a new generation of innovative drugs.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.